NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Zai Lab and NovoCure announced positive Phase 3 PANOVA-3 trial results for Tumor Treating Fields (TTFields) therapy in treating unresectable, locally advanced pancreatic adenocarcinoma, demonstrating a statistically significant improvement in median overall survival to 16.2 months versus 14.2 months with standard treatment. The trial also showed a 6.1-month extension in pain-free survival with TTFields; however, NVCR stock traded down 8.63% following the announcement despite the positive data.

Analysis

Zai Lab Limited (ZLAB) and NovoCure Limited (NVCR) presented additional data from the Phase 3 PANOVA-3 trial for Tumor Treating Fields (TTFields) therapy in unresectable, locally advanced pancreatic adenocarcinoma, revealing a statistically significant improvement in median overall survival (mOS) to 16.2 months for patients treated with TTFields plus standard chemotherapy, compared to 14.2 months for standard chemotherapy alone. This 2.0-month improvement met the trial's primary endpoint. Furthermore, TTFields therapy significantly extended median pain-free survival by 6.1 months, to 15.2 months from 9.1 months, and improved the one-year survival rate to 68.1% versus 60.2%. Despite these clinically positive results presented at the 2025 American Society of Clinical Oncology Annual Meeting, and a safety profile consistent with prior studies with no new signals, NVCR stock traded 8.63% lower to $17.46 following the announcement. While key secondary endpoints like one-year and pain-free survival showed statistically significant improvement, the trial did not demonstrate a statistically significant difference in other secondary outcomes such as progression-free survival or objective response rate. This mixed picture on secondary endpoints, or potentially market expectations for a more substantial mOS benefit, may contribute to the negative market reaction for NVCR, despite the achievement of the primary endpoint.

Key Decisions for Investors

• Investors in NovoCure (NVCR) should carefully weigh the PANOVA-3 trial's primary endpoint success and significant pain-free survival benefit against the stock's 8.63% decline and the lack of statistical significance in some secondary endpoints, suggesting market expectations may not have been fully met or other factors are influencing valuation.
• The positive PANOVA-3 trial data could be viewed more favorably for Zai Lab (ZLAB) as a partner in the development, potentially enhancing its oncology portfolio, especially considering its distinct positive sentiment signal compared to NVCR's immediate market response.
• Consider that while the reported survival gains for TTFields in pancreatic cancer are statistically significant and address a high unmet medical need, the market's reaction to NVCR underscores the importance of evaluating the magnitude of clinical benefit relative to expectations and the broader commercial landscape before making investment decisions.